Literature DB >> 11835208

Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability.

Kieran J Crowley1, George Zografi.   

Abstract

The effect of cryogenic grinding on five crystal forms of indomethacin (IMC) was investigated with particular interest in the formation of amorphous phase. Powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC) demonstrated that amorphous phase formation took place for all three polymorphs (gamma, alpha, and delta) and one solvate (IMC methanolate). In the latter case, a postgrinding drying stage was needed to remove desolvated methanol from the ground amorphous product because methanol destabilized amorphous IMC presumably via a plasticizing effect. The crystal structure of another solvate, IMC t-butanolate, was unaffected by grinding, indicating that amorphous phase formation on grinding does not occur in all cases. Ground amorphous materials possessed similar glass transition temperatures but significant differences in physical stability as assessed by both isothermal and nonisothermal crystallization. It is argued that physical factors, namely residual crystal phase and specific surface area, determine the isothermal and nonisothermal crystallization behavior of ground amorphous samples as opposed to intrinsic differences in the structure of the amorphous phase. Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:492-507, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11835208     DOI: 10.1002/jps.10028

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  34 in total

1.  Effect of aging on the physical properties of amorphous trehalose.

Authors:  Rahul Surana; Abira Pyne; Raj Suryanarayanan
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

2.  Origin of two modes of non-isothermal crystallization of glasses produced by milling.

Authors:  Sayantan Chattoraj; Chandan Bhugra; Chitra Telang; Li Zhong; Zeren Wang; Changquan Calvin Sun
Journal:  Pharm Res       Date:  2011-12-16       Impact factor: 4.200

Review 3.  Stability of amorphous pharmaceutical solids: crystal growth mechanisms and effect of polymer additives.

Authors:  Ye Sun; Lei Zhu; Tian Wu; Ting Cai; Erica M Gunn; Lian Yu
Journal:  AAPS J       Date:  2012-03-21       Impact factor: 4.009

4.  Parallel thermal analysis technology using an infrared camera for high-throughput evaluation of active pharmaceutical ingredients: a case study of melting point determination.

Authors:  Kohsaku Kawakami
Journal:  AAPS PharmSciTech       Date:  2010-07-31       Impact factor: 3.246

5.  Investigation of the milling-induced thermal behavior of crystalline and amorphous griseofulvin.

Authors:  Niraj S Trasi; Stephan X M Boerrigter; Stephen Robert Byrn
Journal:  Pharm Res       Date:  2010-05-18       Impact factor: 4.200

6.  Impact of the amount of excess solids on apparent solubility.

Authors:  Kohsaku Kawakami; Kyoko Miyoshi; Yasuo Ida
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

7.  Mechanically induced amorphization of drugs: a study of the thermal behavior of cryomilled compounds.

Authors:  Niraj S Trasi; Stephen R Byrn
Journal:  AAPS PharmSciTech       Date:  2012-05-15       Impact factor: 3.246

8.  Close intramolecular sulfur-oxygen contacts: modified force field parameters for improved conformation generation.

Authors:  Dmitry Lupyan; Yuriy A Abramov; Woody Sherman
Journal:  J Comput Aided Mol Des       Date:  2012-10-06       Impact factor: 3.686

9.  Solubility of small-molecule crystals in polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA.

Authors:  Jing Tao; Ye Sun; Geoff G Z Zhang; Lian Yu
Journal:  Pharm Res       Date:  2008-12-04       Impact factor: 4.200

10.  The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state.

Authors:  Kieran J Crowley; George Zografi
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.